Morgan Stanley analysts expect AI-fueled drug development to accelerate US life expectancy improvement, lowering benefit ratios for life insurers and supporting EPS. They name Globe Life, RGA, Lincoln, MetLife, and Unum as beneficiaries. Insurers with heavier morbidity/retirement exposure may see a smaller tailwind.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
